FDA OKs Guselkumab for Crohn’s Disease

Guselkumab is the first and only interleukin-23 inhibitor that offers both subcutaneous and intravenous induction options for moderately to severely active Crohn’s disease.
Medscape Medical News

source https://www.medscape.com/viewarticle/fda-oks-guselkumab-crohns-disease-2025a100070a?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost